← Trials/Trial dossier/NCT00934050

CompletedPhase 2Results posted

ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease

Lead sponsor

OPKO Health, Inc.

Asset

ELND005

Listed sites

Recruiting sites

Enrollment

103

actual

Study population

Alzheimer’s disease

Key I/E criterion

Primary endpoint

•Treatment Emergent Adverse Events (TEAEs)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDELND005-AD251

NCT IDNCT00934050

Timeline

Milestones

Study start2009-06 (month precision)

Study first posted2009-07-08estimated

Primary completion2011-06actual (month precision)

Study completion2011-06actual (month precision)

Results first posted2015-05-13estimated

Last update posted2019-10-21actual

Assets

Drug assets

ELND005

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication

Exclusion criteria

•Subject has no new medical contraindications to continued participation in the study.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Treatment Emergent Adverse Events (TEAEs)

Time frame:12 months

event count, event

Primary/registry result

Treatment Emergent Adverse Events (TEAEs)

Time frame:12 months

event count, event

Posted result

Group	Value (number), participants	Reported bounds
Placebo/ELND005 250mg BIDn=26 Participants	21	-
250 mg/ELND005 250 mg BIDn=27 Participants	23	-

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.